𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Expression of interleukin 15 in primary adult acute lymphoblastic leukemia

✍ Scribed by Shuling Wu; Lars Fischer; Nicola Gökbuget; Stefan Schwartz; Thomas Burmeister; Michael Notter; Dieter Hoelzer; Hendrik Fuchs; Igor Wolfgang Blau; Wolf K Hofmann; Eckhard Thiel


Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
182 KB
Volume
116
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

BACKGROUND:

Interleukin‐15 (IL‐15) has been associated with the growth, survival and biological behavior of leukemic cells and response to therapy. We determined the expression of IL‐15 in lymphoblasts and evaluated its potential impact on the outcome in adult acute lymphoblastic leukemia (ALL).

METHODS:

Between June 1999 and June 2006, ALL samples were collected from 87 adult patients before initiation of antineoplastic therapy. These patients were enrolled in the German Multicenter Acute Lymphoblastic Leukemia June 1999 and July 2003 study trials. The expression of IL‐15 in leukemic cells was analyzed by real‐time polymerase chain reaction.

RESULTS:

The expression of IL‐15 correlated with the immunophenotype: T‐lineage ALL had a more than 4‐fold higher IL‐15 mRNA expression as compared with B‐cell precursor (BCP)‐ALL (P < .001). Patients with BCR‐ABL^+^‐BCP‐ALL had lower IL‐15 expression compared with BCR‐ABL^−^‐BCP‐ALL (P = .041). Furthermore, higher expression of IL‐15 was associated with mediastinal (P = .001) and lymph node infiltration (P = .051), but not with hepatomegaly and splenomegaly. Notably, high IL‐15 expression in BCP‐ALL was associated with an inferior relapse‐free survival (RFS) at 5 years (0.17 ± 0.13 vs 0.47 ± 0.13) (P = .008), but there was no impact on overall survival (P = .249).

CONCLUSIONS:

Differential expression of IL‐15 in adult ALL at diagnosis was associated with clinical features and outcome, in particular, RFS. It remains to be evaluated whether IL‐15 might be a relevant therapy target, or might be used for risk stratification. Cancer 2010. © 2010 American Cancer Society.


📜 SIMILAR VOLUMES


Treatment of acute lymphoblastic leukemi
✍ Prof. Tiziano Barbui; Renato Bassan; Teodoro Chisesi; Raffaele Battista; Sergio 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 English ⚖ 276 KB

Thirty-seven adult patients with acute lymphoblastic leukemia were treated with a protocol called HEAV'D including Adriamycin, Vincristine, L-Asparaginase, Cyclophosphamide and Dexamethasone. The complete remission rate was 70 per cent. The median duration of remission was more than 30 months. Patie

In vitro culture with prednisolone incre
✍ Tosi, Patrizia; Visani, Giuseppe; Ottaviani, Emanuela; Manfroi, Silvia; Tura, Sa 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 328 KB 👁 2 views

The presence of BCL-2gene rearrangement has been detected also in cellular populations lacking the t(14;18) chromosomal translocation, such as B-lineage acute lymphobiastic leukemia (ALL) cells. It has been reported that overexpression of BCL-2 is related to resistance to glucocorticoid-induced apop